Patent Grant
10202607
The present disclosure relates generally to compositions and methods for improving recombinant protein production. The recombinant proteins use Ribose Binding Protein for enhancing protein expression.
Many naturally occurring proteins and peptides are of great interest in research, medical, and industrial applications, but obtaining them in sufficient quantities from their natural hosts can be problematic because of low purity or natural abundance. Furthermore, engineering the proteins for altered or improved properties is all but impossible in most native hosts (e.g. insulin from pigs or cows). As a result, scientists have turned to recombinant protein expression in model organisms whose genetics can be manipulated to cause overexpression of proteins not natively found in the host.
For technical reasons, microorganisms like E. coli and S. cerevisiae are the preferred hosts for recombinant protein expression. However, because model microorganisms lack the protein folding machinery and regulatory mechanisms of the organisms from which most proteins of interest originate (e.g. mammals), proteins are often translated poorly or fold improperly from expression constructs (recombinant DNA molecules encoding the protein being produced and other elements necessary for expression), resulting in poor protein expression, solubility and ultimately low yield. There is thus an ongoing and unmet need for improved compositions and methods for improving recombinant protein production.
The present disclosure encompasses compositions and methods for increasing protein production. In general the compositions and methods include expression vectors, recombinant fusion proteins encoded by them, cells comprising the expression vectors, and isolated/purified recombinant fusion proteins, and fragments thereof. The fusion proteins comprise a polypeptide of interest (also referred to herein as a “target protein”) and a segment that comprises a Ribose Binding Protein (RBP), or at least a contiguous portion of an RBP, such that production of the fusion protein is increased. The fusion proteins can be configured to include a segment that is useful for liberating the target protein from the RBP and other non-target protein portions of the fusion protein.
Increases in protein production made possible by the present disclosure can be determined by comparison to any suitable reference, including but not necessarily limited to a value that represents the actual or expected or predicted or calculated expression of the target protein when an RBP segment is not present in the same polypeptide that includes the target protein.
The disclosure is illustrated by non-limiting embodiments that demonstrate RBP-fusion protein production comprising functionally and structurally distinct proteins having different sizes and amino acid profiles. In particular and representative demonstrations, recombinant fusion protein production is illustrated in a prokaryotic system using a modified RBP derived from the RBP produced by Thermoanaerobacter tengcongensis (T. tengcongensis), but it will be apparent that other RBPs can be substituted. In particular embodiments, the disclosure demonstrates recombinant protein production using RBPs expressed in a single polypeptide with human p53, WD-Repeat Protein 5 (WDR5) from Drosophila melanogaster, actin from Saccharomyces cerevisiae, human rhinovirus 3C (HRV 3C) protease, and Mouse double minute 2 homolog (MDM2) also known as E3 ubiquitin-protein ligase Mdm2. The MDM2 has the amino acid sequence of the mouse and human proteins, as they are identical. Thus, the disclosure demonstrates broad applicability to express, and increase expression, of a variety of distinct proteins, and it is expected there are no particular limitations to the type of proteins that can be used in one or more embodiments of the invention.
A representative RBP sequence is provided in SEQ ID NO:2. This sequence comprises a Cys102Ser alternation relative to the wild type T. tengcongensis sequence. Further, it has been determined that enhanced expression of a target protein as a component of a fusion protein described herein does not require the entire length of the RBP. In this regard, in certain embodiments, the disclosure comprises expression vectors, the proteins encoded by them, and other embodiments, wherein the entire RBP segment is not essential. Additionally, the disclosure differs from other systems that have used RBPs in fusion proteins, such as in domain swapping configurations, because the RBP or a segment thereof is provided sequentially with the target protein. As such, in various implementations, the RBP of this disclosure does not interrupt the target protein. In certain approaches, the disclosure includes expression vectors and the fusion proteins encoded by them, wherein the fusion proteins comprise truncations at the N-terminus of the RBP component of from 1-33 amino acids, inclusive and including all integers and all ranges of integers there between, and/or at the C-terminus of the RBP component of from 1-67 amino acids, inclusive and including all integers and all ranges of integers there between. Accordingly, in one approach the disclosure provides a recombinant expression vector encoding a fusion protein comprising sequentially an RBP segment and an uninterrupted target polypeptide, wherein RBP segment comprises at least 178 contiguous amino acids of SEQ ID NO:2, wherein the segment comprises amino acid number 34 (Gly) of SEQ ID NO:2 and amino acid number 211 (Gln) of SEQ ID NO:2. In certain embodiments the expression vector does not encode a signal peptide that targets the fusion protein to periplasm. In some examples an amino acid linker sequence is encoded between the RBP segment and the target protein. In certain examples at least one amino acid sequence tag for purification of the encoded fusion protein is included. In non-limiting embodiments, the target protein may be the only target protein encoded by the expression vector, or in the fusion protein, and in certain embodiments the RBP segment may be the only RBP segment encoded by the expression vector, or in the fusion protein. In certain approaches the fusion protein comprises an amino acid linker sequence, and the linker sequence may optionally comprises a proteolytic cleavage site, such as to liberate the target protein from the fusion protein by cleavage at the proteolytic cleavage site. In certain examples, the fusion protein does not oligomerize in solution with proteins that have the same amino acid sequence of the fusion protein encoded by the expression vector.
In another aspect the disclosure includes a method of making a recombinant fusion protein. The method comprises providing cells at least some of which comprise an expression vector of this disclosure, and allowing expression of the recombinant fusion protein. The fusion protein can be separated from the cells and if desired purified to any desired degree of purity. The target protein can be separated from the fusion protein by, for example, cleaving the fusion protein using any suitable approach or method, including but not limited to cleavage at a proteolytic cleavage site engineered to separate the RBP and the target protein. In certain approaches a cell culture used to express a fusion protein described herein is prokaryotic cell culture, but eukaryotic cell cultures can also be used.
In another aspect the disclosure comprises a method of making a cell culture that is useful for recombinant protein expression. This method comprises introducing an expression vector into a cell culture. The disclosure accordingly includes such cell cultures, their progeny, and further comprises the media in which any cell culture described herein is cultured in. Also included are cell lysates obtained by lysing any cell or population of cells described herein.
In another aspect the disclosure provides a kit. The kit can comprise, for example, an expression vector described herein, and may optionally comprise a restriction endonuclease that recognizes a restriction endonuclease recognition site positioned between the RBP and the target protein. The kit can also include printed instructions for using the expression vector to express the fusion protein.
The disclosure includes any fusion proteins made using a composition, method, and/or kit described herein, and also includes any target polypeptide cleaved from such a fusion protein.
Unless defined otherwise herein, all technical and scientific terms used in this disclosure have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure pertains.
Every numerical range given throughout this specification includes its upper and lower values, as well as every narrower numerical range that falls within it, as if such narrower numerical ranges were all expressly written herein.
Every DNA sequence disclosed herein includes its complementary DNA sequence, and also includes the RNA equivalents thereof. Every DNA and RNA sequence encoding the polypeptides disclosed herein is encompassed by this disclosure, including but not limited to all fusion proteins, and all of the Ribose Binding Protein (RBP) segment of fusion proteins, including but not limited to those comprising N-terminal and/or C-terminal truncations of the RBP segment.
The present disclosure encompasses compositions and methods for improving production of recombinantly produced protein. In embodiments the disclosure comprises recombinant expression vectors and methods of using them to produce proteins. In general the expression vectors encode at least one fusion protein comprising a segment that includes a polypeptide of interest (also referred to herein as a “target protein”) and a segment that comprises a Ribose Binding Protein (RBP) or at least a contiguous portion of an RBP.
In embodiments, the RBP encoded by the expression vector comprises an RBP from a prokaryote, such as an archaea, which may be a thermophilic and/or anaerobic microorganism. In an embodiment, the RBP is from Thermoanaerobacter tengcongensis (T. tengcongensis), which is referred to herein as “tteRBP.” In embodiments, the RBP comprises a functional homologue, fragment, or derivative of tteRBP or a segment thereof which retains the capability to enhance production of a fusion protein into which it is inserted. Enhanced protein production means in one embodiment that more of the fusion protein is produced than a value for a suitable reference. In embodiments, the reference can be a value obtained by production of the protein into which the RBP or segment thereof has not been inserted. In embodiments, the disclosure includes increasing production of a recombinant protein by at least 10% relative to a reference, and can comprise increasing production of a recombinant protein by from 10%-80%, inclusive, relative to a reference, or more than 80% relative to a reference.
In embodiments, the RBP comprises an amino acid sequence that is at least 80% similar to SEQ ID NO:2, or to a contiguous segment of SEQ ID NO:2. In embodiments, the RBP comprises an amino acid sequence that is 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQ ID NO:2 or a segment of it, for example, a segment that comprises at least 178 amino acids. Thus, in certain embodiments, an RBP segment of this disclosure comprises variations in sequence relative to SEQ ID NO:2. Such variations can comprise conservative or non-conservative amino acid substitutions, insertions, and deletions. In embodiments, the RBP component of the fusion protein comprises a mutation relative to its naturally occurring sequence. In one embodiment the mutation is a Cys102Ser alteration. In certain implementations, the RBP component of a fusion protein lacks a signal peptide, and thus the disclosure also includes entire fusion proteins which lack a signal peptide. The term “lacks a signal peptide” means either the construct may in fact lack the signal peptide sequence, or the signal peptide may simply be modified to lack signal peptide function. In an embodiment, the fusion protein lacks a signal peptide that functions to transport the protein to the periplasm (N-terminal amino acid sequence RKSRILLLLTIFVTSAALILSGCKTNTPNTASTST (SEQ ID NO:17).
In embodiments the RBP component of the fusion protein is a segment of a full-length RBP (but lacking a signal sequence). We have also determined if 34 or more amino acids are removed from the N-terminus, or 68 or more amino acids are removed from the C-terminus, the protein loses much of its stability and native structure/function as measured by melting temperature, far UV circular dichroism spectrum, 2D NMR spectrum, and ribose binding ability. Thus, it is considered that a truncation of the first 34 or more N-terminal amino acids, or the last 68 or more C-terminal amino acids of SEQ ID NO:2, exceeds the limits of how much the ends of the tteRBP component can be shortened, yet still function to increase expression and solubility. However, an RBP component of the fusion protein that has shorter truncations of amino acids at its N-terminus, its C-terminus, or at both the N- and C-termini, may still have utility as a solubility and expression tag. Therefore, the disclosure includes fusion proteins which comprise truncations at the N-terminus of the RBP component of from 1-33 amino acids, inclusive and including all integers and all ranges of integers there between, and at the C-terminus of the RBP component of from 1-67 amino acids, inclusive and including all integers and all ranges of integers there between.
In embodiments, the RBP component of the fusion protein comprises a contiguous segment of SEQ ID NO:2 that includes amino acid number 34 of SEQ ID NO:2 at its N terminus. In embodiments, the RBP component of the fusion protein comprises a contiguous segment of SEQ ID NO:2 that includes the amino acid at position 211 of SEQ ID NO:2 at its C-terminus. In embodiments, the RBP component of the fusion protein comprises a contiguous segment of SEQ ID NO:2 that comprises or consists of a segment of SEQ ID NO:2 having the amino acid at position 34 and the amino acid at position 211 of SEQ ID NO:2 at its N- and C-terminus, respectively. In embodiments, the RBP component of the fusion protein is from 278 to 211 amino acids in length. In one embodiment, the RBP component is at least 244 amino acids in length. In embodiments, the fusion protein comprises a tteRBP component lacking the signaling peptide and comprising amino acids 1-211, 1-259, or 34-278, of SEQ ID NO:2. SEQ ID NO:2 is:
MKEGKTIGLVISTLNNPFFVTLKNGAEEKAKELGYKIIVEDSQNDSSKELSNVEDLIQQKVDVLLINPVDSDAVVTA IKEANSKNIPVITIDRSANGGDVVSHIASDNVKGGEMAAEFIAKALKGKGNVVELEGIPGASAARDRGKGFDEAIAK YPDIKIVAKQAADFDRSKGLSVMENILQAQPKIDAVFAQNDEMALGAIKAIEAANRQGIIVVGFDGTEDALKAIKEG KMAATIAQQPALMGSLGVEMADKYLKGEKIPNFIPAELKLITKENVQ. The bold italicized amino acids indicate those that have been determined in accordance with this invention to be dispensable for use in the enhanced protein production approaches of this disclosure.
In embodiments, the fusion proteins do not comprise ubiquitin. In embodiments the fusion proteins do not comprise any segment of ubiquitin that can enhance production of the fusion protein in which the ubiquitin segment is contained, relative to production of an otherwise same fusion protein but in which the ubiquitin segment is not present. In embodiments the fusion proteins do not comprise a ubiquitin-like protein, Apoptosis Stimulating Protein of p53 2 (“ASPP2”), an isoform of ASPP2, or General Control Protein 4 (“GCN4”). In embodiments the fusion proteins of the present disclosure do not bind to one another in solution, and/or do not oligomerize, and/or do not undergo domain swapping with one another and thus do not bind to other of the same or similar fusion proteins in trans, and/or do not bind to one another in cis. In an embodiment, the fusion proteins do not form a network, such as a branched network, or a gel comprising the fusion proteins. In embodiments, fusion proteins of this disclosure retain their native-like structure, which can be determined, for example, using near-UV circular dichroism spectroscopy (CD), electrophoretic mobility shift assay (EMSA), gel-filtration chromatography, or any other suitable approach for determining protein structure. In embodiments, isolated fusion proteins of this disclosure retain their native-like structure. In embodiments, a fusion protein of this disclosure may comprise only a single RBP, even if the RBP is interrupted by a distinct polypeptide sequence. In embodiments a fusion protein of this disclosure can include only one protein of interest, which may be N-terminal to the RBP segment, C-terminal to the RBP segment, or flanked by RBP segments.
A representative polynucleotide sequence encoding tteRBP is provided in SEQ ID NO:1. Those skilled in the art will recognize that, due to the redundancy of the genetic code, there are a multitude of polynucleotide sequences that can encode tteRBP, and each of these sequences is included within the scope of this disclosure. This also pertains to the other DNA sequences that encode representative and non-limiting examples of fusion proteins provided by this disclosure as further described in the Examples.
The polypeptide encoded by the expression vector along with the RBP segment may be any polypeptide of interest. A target polypeptide according to the present disclosure may be any polypeptide required or desired in larger amounts and therefore may be difficult to isolate or purify from other sources. Non-limiting examples of target proteins that can produced by the present methods include mammalian gene products, such as enzymes, cytokines, growth factors, hormones, vaccines, antibodies and the like. In embodiments, overexpressed gene products of the present disclosure include gene products such as erythropoietin, insulin, somatotropin, growth hormone releasing factor, platelet derived growth factor, epidermal growth factor, transforming growth factor a, transforming growth factor 13, epidermal growth factor, fibroblast growth factor, nerve growth factor, insulin-like growth factor I, insulin-like growth factor II, clotting Factor VIII, superoxide dismutase, α-interferon, γ-interferon, interleukin-1, interleukin-2, interleukin-3, interleukin-4, interleukin-5, interleukin-6, granulocyte colony stimulating factor, multi-lineage colony stimulating activity, granulocyte-macrophage stimulating factor, macrophage colony stimulating factor, T cell growth factor, lymphotoxin and the like. In embodiments overexpressed gene products are human gene products. The present methods can readily be adapted to enhance secretion of any overexpressed gene product which can be used as a vaccine. Overexpressed gene products which can be used as vaccines include any structural, membrane-associated, membrane-bound or secreted gene product of a mammalian pathogen. Mammalian pathogens include viruses, bacteria, single-celled or multi-celled parasites which can infect or attack a mammal. For example, viral vaccines can include vaccines against viruses such as human immunodeficiency virus (HIV), vaccinia, poliovirus, adenovirus, influenza, hepatitis A, hepatitis B, dengue virus, Japanese B encephalitis, Varicella zoster, cytomegalovirus, hepatitis A, rotavirus, as well as vaccines against viral diseases like measles, yellow fever, mumps, rabies, herpes, influenza, parainfluenza and the like. Bacterial vaccines can include vaccines against bacteria such as Vibrio cholerae, Salmonella typhi, Bordetella pertussis, Streptococcus pneumoniae, Hemophilus influenza, Clostridium tetani, Corynebacterium diphtheriae, Mycobacterium leprae, R. rickettsii, Shigella, Neisseria gonorrhoeae, Neisseria meningitidis, Coccidioides immitis, Borellia burgdorferi, and the like. A target polypeptide may also comprise sequences; e.g., diagnostically relevant epitopes, from several different proteins constructed to be expressed as a single recombinant polypeptide.
Variants of the RBP or target protein bearing one or several amino acid substitutions or deletion are also included in this disclosure. The skilled artisan can easily assess whether such variants, e.g., fragments or mutants are appropriate for a method of this disclosure by, for example, using the procedures as described in the Examples.
As described above, in embodiments the present disclosure provides polypeptides comprising at least one polypeptide domain corresponding to the tteRBP used as an expression tool and at least one polypeptide domain corresponding to the target protein. In embodiments, the tteRBP component is referred to as a solubility and expression tag.
A representative and non-limiting configuration of a fusion protein of this disclosure is provided in
In embodiments the DNA construct of the present disclosure encodes a fusion protein comprising a polypeptide linker in between the polypeptide sequence corresponding to the tteRBP-solubility and expression tag and the polypeptide sequence corresponding to the target protein. Such a DNA sequence coding for a linker, in addition to e.g., providing for a proteolytic cleavage site, may also serve as a polylinker, i.e., it may provide multiple DNA restriction sites to facilitate fusion of the DNA fragments coding for a target protein and a solubility and expression tag domain.
In a further embodiment, the disclosure includes a recombinant DNA molecule, such as an expression vector, encoding a fusion protein, comprising operatively-linked at least one nucleotide sequence coding for a target polypeptide and upstream thereto at least one nucleotide sequence coding for a tteRBP.
Polynucleotide sequences are operatively-linked when they are placed into a functional relationship with another polynucleotide sequence. For instance, a promoter is operatively-linked to a coding sequence if the promoter affects transcription or expression of the coding sequence. Generally, operatively-linked means that the linked sequences are contiguous and, where necessary to join two protein coding regions, both contiguous and in reading frame. However, it is well known that certain genetic elements, such as enhancers, may be operatively-linked even at a distance, i.e., even if not contiguous. Promoters of the present disclosure may be endogenous or heterologous to the host, and may be constitutive or inducible.
DNA constructs prepared for introduction into a host typically comprise a replication system recognized by the host, including the intended DNA fragment encoding the desired target fusion peptide, and will can also include transcription and translational initiation regulatory sequences operatively-linked to the polypeptide encoding segment. Expression systems (expression vectors) may include, for example, an origin of replication or autonomously replicating sequence (ARS) and expression control sequences, a promoter, an enhancer and necessary processing information sites, such as ribosome-binding sites, RNA splice sites, polyadenylation sites, transcriptional terminator sequences, and mRNA stabilizing sequences.
The appropriate promoter and other necessary vector sequences are selected so as to be functional in the host. Examples of workable combinations of cell lines and expression vectors include but are not limited to those described Sambrook, J., et al., in “Molecular Cloning: A Laboratory Manual” (1989, 4th edition: 2012)-, Eds. J. Sambrook, E. F. Fritsch and T. Maniatis, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, or Ausubel, F., et al., in “Current Protocols in Molecular Biology” (1987 and periodic updates), Eds. F. Ausubel, R. Brent and K. R. E., Wiley & Sons Verlag, New York; and Metzger, D., et al., Nature 334 (1988) 31-6. Many useful vectors for expression in bacteria, yeast, mammalian, insect, plant or other cells are known in the art and may be obtained from vendors including, but not limited to, Stratagene, New England Biolabs, Promega Biotech, and others. In addition, the construct may be joined to an amplifiable gene (e.g., DHFE) so that multiple copies of the gene may be obtained.
Expression and cloning vectors can contain a selectable marker, a gene encoding a protein necessary for the survival or growth of a host cell transformed with the vector, although such a marker gene may be carried on another polynucleotide sequence co-introduced into the host cell. Only those host cells expressing the marker gene will survive and/or grow under selective conditions. Typical selection genes include but are not limited to those encoding proteins that (a) confer resistance to antibiotics or other toxic substances, e.g., ampicillin, tetracycline, etc.; (b) complement auxotrophic deficiencies; or (c) supply critical nutrients not available from complex media. The choice of the proper selectable marker will depend on the host cell, and appropriate markers for different hosts are known in the art.
The expression vectors containing the polynucleotides of interest can be introduced into the host cell by any method known in the art. These methods vary depending upon the type of cellular host, including but not limited to transfection employing calcium chloride, rubidium chloride, calcium phosphate, DEAE-dextran, other substances, and infection by viruses. Large quantities of the polynucleotides and polypeptides may be prepared by expressing the polynucleotides in compatible host cells. The most commonly used prokaryotic hosts are strains of Escherichia coli, although other prokaryotes, such as Bacillus subtilis may also be used.
Construction of a vector according to the present disclosure employs conventional ligation techniques. Isolated plasmids or DNA fragments are cleaved, tailored, and religated in the form desired to generate the plasmids required. If desired, analysis to confirm correct sequences in the constructed plasmids is performed in a known fashion. Suitable methods for constructions expression vectors, preparing in vitro transcripts, introducing DNA into host cells, and performing analyses for assessing expression and function are known to those skilled in the art.
The DNA construct comprising two solubility and expression tag domains as well as a target polypeptide domain may also contains two linker peptides in between these domains. In order to allow for systematic cloning, the nucleotide sequences coding for these two linker peptide sequences may be different from one another. This difference in nucleotide sequence can result in a difference in the amino-acid sequence of the linker peptides, but the amino acid sequences of the two linker peptides may also be identical. Such identical linker peptide sequences for example are advantageous if the fusion protein comprising two tteRBP-solubility and expression tag domains as well as their target protein domain is to be used in an immunoassay.
In cases where it is desired to release one or all of the solubility and expression tags out of a fusion protein, the linker peptide can be constructed to comprise a proteolytic cleavage site. Thus, a recombinant DNA molecule, such as an expression vector, encoding a fusion protein comprising at least one polynucleotide sequence coding for a target polypeptide, upstream thereto at least one polynucleotide sequence coding for a tteRBP-solubility and expression tag with the signaling peptide removed, and additionally comprising a nucleic acid sequence coding for a peptidic linker comprising a proteolytic cleavage site, represents a non-limiting embodiment of this invention. In certain embodiments, the expression vector comprises codons optimized for expression in the host cell.
The recombinant proteins of the inventions can be recovered by conventional methods. Thus, where the host cell is bacterial, such as E. coli it may be lysed physically, chemically or enzymatically and the protein product isolated from the resulting lysate. It is then purified using conventional techniques, including but not necessarily limited to conventional protein isolation techniques such as selective precipitation, adsorption chromatography, and affinity chromatography, including but not limited to a monoclonal antibody affinity column.
In embodiments the fusion proteins comprise a tag for facilitating separation, isolation and/or purification. For example, when the proteins of the present invention are expressed with a histidine tail (HIS tag), they can easily be purified by affinity chromatography using an ion metal affinity chromatography column (IMAC) column.
In one embodiment, the proteins comprise an affinity peptide, such as a Histidine tail, fused at the carboxy-terminus of the proteins of the invention. In embodiments the His tag comprises between 5 to 8 histidine residues, or at least 4 His residues, or 6 His residues. In embodiments the affinity peptide has adjacent histidine residues, such as at least two, three or four. In an embodiment the protein comprises 6 directly neighboring histidine residues. In another embodiment, the proteins comprise a C-LYTA tag at their carboxy-terminus. Lyta is derived from Streptococcus pneumoniae which synthesize an N-acetyl-L-alanine amidase, amidase LYTA, (coded by the lytA gene {Gene, 43 (1986) page 265-272} an autolysin that specifically degrades certain bonds in the peptidoglycan backbone. The C-terminal domain of the LYTA protein is responsible for the affinity to the choline or to some choline analogues such as DEAE. This property has been exploited for the development of E. coli C-LYTA expressing plasmids useful for expression of fusion proteins. Purification of hybrid proteins containing the C-LYTA fragment at its amino terminus has been described {Biotechnology: 10, (1992) page 795-798}.
When used as part of an expression construct designed for the expression of the coded protein in an appropriate host (e.g. a bacterial expression plasmid in E. Coli, pCDFDuet-1 and pET-23 used with BL21(DE3) in Example 1), the disclosure produces a novel fusion protein, from which the protein of interest can be readily purified, in certain embodiments at substantially higher levels than can be achieved using only the sequence for the protein of interest alone.
Fusion polypeptides can be purified to high levels (greater than 80%, or greater than 90% pure, as visualized by SDS-PAGE) by undergoing further purification steps. An additional purification step is a Q-Sepharose step that may be operated either before or after the IMAC column to yield highly purified protein. They present a major single band when analyzed by SDS PAGE under reducing conditions, and western blot analysis show less than 5% host cell protein contamination.
The fusion proteins of the invention may be expressed in unicellular hosts such as prokaryotic and lower eukaryotic organisms, such as yeast and bacteria. In an embodiment the fusion are expressed in E. coli.
In one aspect, the present disclosure relates to a method of producing a fusion protein. The method comprises the steps of culturing a host cell transformed with an expression vector as described above, expression of that fusion protein in the respective host cell and separating the protein from the cell culture. The expression system is demonstrated to function with biochemically distinct target proteins, e.g., p53, cellulase 6B and 5A from Thermobifida fusca and cellulase from Pyrococcus horikoshii, WD-repeat containing protein 5 (WDR5) from Drosophila melanogaster, and actin. As can be readily seen from the Examples of this disclosure, specifically relating to these proteins, the efficient expression systems function and result in high levels of fusion protein produced. Similar findings have been made with a variety of other target proteins expressed as fusion proteins.
Further, we demonstrate that the target protein comprised in a fusion protein produced according to the present disclosure can be obtained in a native-like structure. Such native-like structure and function, e.g., for p53 and cellulases, has been confirmed by near-UV circular dichroism spectroscopy (CD), electrophoretic mobility shift assay (EMSA), and gel-filtration chromatography. For p53, near-UV CD spectroscopy reveals a folded protein with mixed alpha helix and beta strand character, EMSA reveals high-affinity site-specific binding to DNA including the p53 consensus recognition sequence, and gel-filtration reveals the correct “tetrameric” oligomeric state, which is well known in the art. Cellulases were confirmed native and functional by cellulose filter paper digestion, Avicel digestion, and soluble carboxymethyl cellulose digestion assays, which are well known cellulase activity assays in the art.
Compositions comprising fusion proteins, or proteins liberated from the tteRBP, are also provided. Such compositions include but are not necessarily limited to compositions that comprise a pharmaceutically acceptable excipient and thus are suitable for human and veterinary prophylactic and/or therapeutic approaches.
In another embodiment, kits for producing fusion proteins according to this disclosure are provided. The kits can provide one or more expression vectors described herein, as well as printed instructions for using the vectors, and/or for recovering the overexpressed protein.
The following specific examples are provided to illustrate the invention, but are not intended to be limiting in any way.
This Example demonstrates a fusion protein of the present invention that comprises full length p53 expressed in E. coli BL21(DE3).
Expression Plasmids.
The full-length human p53 gene (coding sequence for amino acids 1-393) was fused to the 3′ end of either an oligonucleotide coding for an N-terminal 6×His tag followed by the human rhinovirus 3C (HRV 3C) protease recognition site (LEVLFN/GP) and placed under the control of a T7 promoter in the pET23 expression vector (EMD Millipore, Billerica, Mass.), or to the 3′ end of an oligonucleotide coding for an N-terminal 6×His tag followed by tteRBP, an linker and a HRV3C protease recognition site and placed under the control of a T7 promoter in the pCDF-Duet1 expression vector (EMD Millipore, Billerica, Mass.). The nucleotide and resultant fusion protein sequences can be seen in Table 1.
Protein Expression and Partial Purification.
BL21(DE3) cells made competent by CaCl2 permeabilization were transformed with the expression plasmids, plated on LB Agar plates containing 50 μg/mL ampicillin (for pET23) or streptomycin (for pCDFDuet-1), and grown at 37° C. for ˜18 hrs. Isolated colonies were then picked and grown in batch culture (1 L baffled flasks) at 37° C. in LB containing 50 μg/mL appropriate antibiotic with 200 RPM continuous shaking until OD600=0.6. The temperature was then dropped to 20° C. and the cultures induced with 20 mg/L IPTG and grown for ˜18 hrs. Cells were harvested by centrifugation, resuspended in resuspension/wash buffer (20 mM Tris pH 7.2, 300 mM NaCl, 10 mM Imidazole, and 10 mM β-mercaptoethanol), and lysed by incubation with egg white lysozyme and DNAase I+5 mM MgCl2 on ice for 60 min. Insoluble material was pelleted by centrifugation, and the clarified supernatant loaded on to a Ni2+-NTA column pre-equilibrated with resuspension/wash buffer. After washing, the sample was eluted with 20 mM Tris pH 7.2, 300 mM NaCl, 250 mM Imidazole, and 10 mM β-mercaptoethanol. Protein-containing fractions were then pooled, dialyzed against 20 mM Tris, 150 mM NaCl, 10 mM β-mercaptoethanol, and the tags removed by incubation with GST-tagged HRV 3C protease (0.05-0.1 mg protease/mg p53) for ˜18 hrs at 4° C. Samples were subjected to denaturing, reducing SDS-PAGE (samples prepared by boiling in 1× Lamelli Buffer+10% β-mercaptoethanol for 5 min) and visualized by staining with Coumassie Brilliant Blue.
Results
After Ni2+-NTA chromatography, a band corresponding to the correct molecular weight of 6×His-HRV3Csite-p53 or the 6×His-tteRBP-HRV3Csite-p53 fusion protein can be seen. However, the band in the 6×His-HRV3Csite-p53 lane is faint, and is not significantly more intense than many of the impurities (
This example demonstrates tteRBP as an expression tag for WD-Repeat Protein 5 (WDR5) from Drosophila melanogaster in E. coli.
Expression Plasmids
The coding sequence for WDR5 from Drosophila melanogaster was fused to the 3′ end of either an oligonucleotide coding for an N-terminal 6×His tag and placed under the control of a T7 promoter in the pHis-parallel1 expression vector (NCBI GenBank AF097413.1), or to the 3′ end of an oligonucleotide coding for an N-terminal 6×His tag followed by tteRBP, an linker and a HRV3C protease recognition site and placed under the control of a T7 promoter in the pCDF-Duet1 expression vector (EMD Millipore, Billerica, Mass.). The nucleotide and resultant fusion protein sequences can be seen in Table 1.
Protein Expression and Purification
BL21(DE3) cells made competent by CaCl2 permeabilization were transformed with the expression plasmids, plated on LB Agar plates containing 50 μg/mL streptomycin for pCDF-Duet1 or ampicillinfor pHis-parallel1, and grown at 37° C. for ˜18 hrs. Isolated colonies were then picked and grown in batch culture (5 mL tubes) at 37° C. in LB containing 50 μg/mL streptomycin 50 μg/mL streptomycin for pCDF-Duet1 or ampicillinfor pHis-parallel1 with 200 RPM continuous shaking until OD600=0.6. Cultures were induced with 20 mg/L IPTG and grown at for ˜18 hrs. Samples taken before induction and after 18 hrs induction were lysed by boiling in cracking buffer (1× lamelli buffer+4 M Urea+10% β-mercaptoethanol) for 5 min, and subjected to SDS-PAGE. Whole cell lysates were then visualized by staining with Coumassie Brilliant Blue.
Results
Bands corresponding to the predicted molecular weight of both the untagged and tteRBP tagged proteins can be seen in their respective lanes that are not present in the uninduced sample (
This Example demonstrates use of tteRBP as an expression tag in E. coli BL21(DE3) for the expression of Actin.
Expression Plasmids
The full-length human actin gene was fused to the 3′ end of an oligonucleotide coding for an N-terminal 6×His tag followed by tteRBP, an linker and a HRV3C protease recognition site and placed under the control of a T7 promoter in the pCDF-Duet1 expression vector (EMD Millipore, Billerica, Mass.). The nucleotide and resultant fusion protein sequences can be seen in Table 1.
Protein Expression
BL21(DE3) cells made competent by CaCl2 permeabilization were transformed with the expression plasmids, plated on LB Agar plates containing 50 μg/mL streptomycin, and grown at 37° C. for ˜18 hrs. Isolated colonies were then picked and grown in batch culture (50 mL unbaffled flasks) at 37° C. in LB containing 50 μg/mL streptomycin with 225 RPM continuous shaking until OD600=0.6. Cultures were then cooled to 20° C. and induced with 20 mg/L IPTG and grown at for ˜18 hrs. Cells were harvested by centrifugation, resuspended in resuspension/wash buffer (20 mM Tris pH 7.2, 300 mM NaCl, 10 mM Imidazole, and 10 mM β-mercaptoethanol), and lysed by incubation with egg white lysozyme and DNAase I+5 mM MgCl2 on ice for 60 min. The fusion protein expressed as inclusion bodies, which were pelleted by centrifugation and washed 3 times in buffer and 1 M NaCl. The pellet was then dissolved in 20 mM Tris pH 7.2, 300 mM NaCl, 10 mM Imidazole, 10 mM β-mercaptoethanol+6 M guanidine-hydrochloride and loaded onto an Ni2+-NTA column pre-equilibrated with the same buffer. After washing, the sample was eluted with 20 mM Tris pH 7.2, 300 mM NaCl, 250 mM Imidazole, and 10 mM β-mercaptoethanol. Protein-containing fractions were then pooled, and refolded by 20-fold rapid dilution into 20 mM Tris, 150 mM NaCl, 10 mM β-mercaptoethanol. Samples were subjected to denaturing, reducing SDS-PAGE (samples prepared by boiling in 1× Lamelli Buffer+10% β-mercaptoethanol for 5 min) and visualized by staining with Coumassie Brilliant Blue.
Results
The resultant protein was soluble and resulted in a single homogenous band by SDS-PAGE. This is a substantial improvement over previous attempts at IPTG-inducible recombinant expression of human actin in E. coli, which has previously been demonstrated to yield little to no soluble protein at these temperatures [Production of human beta actin and a mutant using bacterial expression system with a cold shock vector, Tamura M et al, Protein Expression and Purification (2010)].
This example demonstrates a fusion protein of the present invention that comprises and RBP fusion with HRV3C protease.
Expression Plasmid
The sequence for HRV3C protease was fused to the 3′ end of an oligonucleotide coding for an N-terminal 6×His tag followed by tteRBP and placed under the control of a T7 promoter in the pCDF-Duet1 expression vector (EMD Millipore, Billerica, Mass.).
Protein Expression and Purification
BL21(DE3) cells made competent by CaCl2 permeabilization were transformed with the expression plasmids, plated on LB Agar plates containing 50 μg/mL streptomycin and grown at 37° C. for ˜18 hrs. Isolated colonies were then picked and grown in batch culture (1 L baffled flasks) at 37° C. in LB containing 50 μg/mL streptomycin with 200 RPM continuous shaking until OD600=0.6. The temperature was then dropped to 18° C. and the cultures induced with 20 mg/L IPTG and grown for ˜18 hrs. Cells were harvested by centrifugation, resuspended in resuspension/wash buffer (20 mM Tris pH 8.0, 300 mM NaCl, 10 mM Imidazole, and 10 mM β-mercaptoethanol), and lysed by incubation with egg white lysozyme and DNAase I+5 mM MgCl2 on ice for 60 min. Insoluble material was pelleted by centrifugation, and the clarified supernatant loaded on to a Ni2+-NTA column pre-equilibrated with resuspension/wash buffer. After washing, the sample was eluted with 20 mM Tris pH 8.0, 300 mM NaCl, 250 mM Imidazole, and 10 mM β-mercaptoethanol. Protein-containing fractions were then pooled, dialyzed against 20 mM Tris, 10 mM β-mercaptoethanol. Samples were then further purified by Q-sepharose chromatography in the same buffer with a 0-1M NaCl gradient. Samples were subjected to denaturing, reducing SDS-PAGE (samples prepared by boiling in 1× Lamelli Buffer+10% β-mercaptoethanol for 5 min) and visualized by staining with Coumassie Brilliant Blue. Prescission protease (GST-fused HRV3C protease) was obtained from GE Healthcare Life Sciences for comparison.
Results
We were able to purify a protein was purified with a molecular weight consistent with the fusion protein, with the only major impurity being a band with a molecular weight consistent with the free-RBP tag (
This example demonstrates an RBP fusion protein that comprises full length MDM2, a ubiquitin E3 ligase.
Expression Plasmid.
The full-length human MDM2 gene was fused to the 3′ end of an oligonucleotide coding for an N-terminal 6×His tag followed by tteRBP, an linker and a HRV3C protease recognition site and placed under the control of a T7 promoter in the pCDF-Duet1 expression vector (EMD Millipore, Billerica, Mass.).
Protein Expression and Purification
BL21(DE3) cells made competent by CaCl2 permeabilization were transformed with the expression plasmid, plated on LB Agar plates containing 50 μg/mL streptomycin, and grown at 37° C. for ˜18 hrs. Isolated colonies were then picked and grown in batch culture (1 L baffled flasks) at 37° C. in LB containing 50 μg/mL streptomycin with 200 RPM continuous shaking until OD600=0.6. The temperature was then dropped to 18° C. and the cultures induced with 20 mg/L IPTG and grown for ˜18 hrs. Cells were harvested by centrifugation, resuspended in resuspension/wash buffer (20 mM Tris pH 8.0, 300 mM NaCl, 10 mM Imidazole, and 10 mM β-mercaptoethanol), and lysed by incubation with egg white lysozyme and DNAase I+5 mM MgCl2 on ice for 60 min. Insoluble material was pelleted by centrifugation, and the clarified supernatant loaded on to a Ni2+-NTA column pre-equilibrated with resuspension/wash buffer. After washing, the sample was subjected to on-column tag cleavage with GST-tagged HRV 3C protease (0.05-0.1 mg protease/mg p53) for ˜18 hrs at 4° C. The protein was then collected, and samples were subjected to denaturing, reducing SDS-PAGE (samples prepared by boiling in 1× Lamelli Buffer+10% β-mercaptoethanol for 5 min) and visualized by staining with Coumassie Brilliant Blue.
Results
We were able to purify a protein that migrated at a molecular weight consistent with MDM2. We were able to confirmed its identity by western blot, and also found that this protein bound to full-length p53. Thus, this example demonstrates yet another embodiment of this disclosure in the form of an RBP/MDM2 fusion protein.
MKEGKTIGLVISTLNNPFFVTLKNGAEEKAKELGYKIIVEDSQNDSSKELSNVEDLIQQK
VDVLLINPVDSDAVVTAIKEANSKNIPVITIDRSANGGDVVSHIASDNVKGGEMAAEFIA
KALKGKGNVVELEGIPGASAARDRGKGFDEAIAKYPDIKIVAKQAADFDRSKGLSVMENI
LQAQPKIDAVFAQNDEMALGAIKAIEAANRQGIIVVGFDGTEDALKAIKEGKMAATIAQQ
PALMGSLGVEMADKYLKGEKIPNFIPAELKLITKENVQ
QNDSSKELSNVEDLIQQKVDVLLINPVDSDAVVTAIKEANSKNIPVITIDRSANGGDVVS
HIASDNVKGGEMAAEFIAKALKGKGNVVELEGIPGASAARDRGKGFDEAIAKYPDIKIVA
KQAADFDRSKGLSVMENILQAQPKIDAVFAQNDEMALGAIKAIEAANRQGIIVVGFDGTE
DALKAIKEGKMAATIAQQPALMGSLGVEMADKYLKGEKIPNFIPAELKLITKENVQGGAA
VLSPLPSQAMDDLMLSPDDIEQWFTEDPGPDEAPRMPEAAPPVAPAPAAPTPAAPAPAPS
WPLSSSVPSQKTYQGSYGFRLGFLHSGTAKSVTCTYSPALNKMFCQLAKTCPVQLWVDST
PPPGTRVRAMAIYKQSQHMTEVVRRCPHHERCSDSDGLAPPQHLIRVEGNLRVEYLDDRN
TERHSVVVPYEPPEVGSDCTTIHYNYMCNSSCMGGMNRRPILTIITLEDSSGNLLGRNSF
EVRVCACPGRDRRTEEENLRKKGEPHHELPPGSTKRALPNNTSSSPQPKKKPLDGEYFTL
QIRGRERFEMFRELNEALELKDAQAGKEPGGSRAHSSHLKSKKGQSTSRHKKLMEKTEGP
DSD
SPDDIEQWFTEDPGPDEAPRMPEAAPPVAPAPAAPTPAAPAPAPSWPLSSSVPSQKTYQG
SYGFRLGFLHSGTAKSVTCTYSPALNKMFCQLAKTCPVQLWVDSTPPPGTRVRAMAIYKQ
SQHMTEVVRRCPHHERCSDSDGLAPPQHLIRVEGNLRVEYLDDRNTERHSVVVPYEPPEV
GSDCTTIHYNYMCNSSCMGGMNRRPILTIITLEDSSGNLLGRNSFEVRVCACPGRDRRTE
EENLRKKGEPHHELPPGSTKRALPNNTSSSPQPKKKPLDGEYFTLQIRGRERFEMFRELN
EALELKDAQAGKEPGGSRAHSSHLKSKKGQSTSRHKKLMFKTEGPDSD
PNSVGQPGATTSSNSSASNKSSLSVKPNYTLKFTLAGHTKAVSAVKFSPNGEWLASSSAD
KLIKIWGAYDGKEEKTISGHKLGISDVAWSSDSRLLVSGSDDKTLKVWELSTGKSLKTLK
GHSNYVFCCNENPQSNLIVSGSFDESVRIWDVRTGKCLKTLPAHSDPVSAVHFNRDGSLI
VSSSYDGLCRIWDTASGQCLKTLIDDDNPPVSFVKFSPNGKYILAATLDNTLKLWDYSKG
KCLKTYTGHKNEKYCIFANFSVTGGKWIVSGSEDNMVYIWNLQSKEVVQKLQGHTDTVLC
TACHPTENIIASAALENDKTIKLWKSDT
QNDSSKELSNVEDLIQQKVDVLLINPVDSDAVVTAIKEANSKNIPVITIDRSANGGDVVS
HIASDNVKGGEMAAEFIAKALKGKGNVVELEGIPGASAARDRGKGFDEAIAKYPDIKIVA
KQAADFDRSKGLSVMENILQAQPKIDAVFAQNDEMALGAIKATEAANROGIIVVGFDGTE
DALKAIKEGKMAATIAQQPALMGSLGVEMADKYLKGEKIPNFIPAELKLITKENVQGGAA
GAYDGKEEKTISGHKLGISDVAWSSDSRLLVSGSDDKTLKVWELSTGKSLKTLKGHSNYV
FCCNENPQSNLIVSGSFDESVRIWDVRTGKCLKTLPAHSDPVSAVHFNRDGSLIVSSSYD
GLCRIWDTASGQCLKTLIDDDNPPVSFVKFSPNGKYILAATLDNTLKLWDYSKGKCLKTY
AALENDKTIKLWKSDT
ONDSSKELSNVEDLIQQKVDVLLINPVDSDAVVTAIKEANSKNIPVITIDRSANGGDVVS
HIASDNVKGGEMAAEFIAKALKGKGNVVELEGIPGASAARDRGKGFDEAIAKYPDIKIVA
KQAADFDRSKGLSVMENILQAOPKIDAVFAONDEMALGAIKAIEAANRCGIIVVGFDGTE
DALKAIKEGKMAATIAQOPALMGSLGVEMADKYLKGEKIPNFIPAELKLITKENVQGGAA
HQGIMVGMGQKDSYVGDEAQSKRGILTLRYPIEHGIVTNWDDMEKIWHHTFYNELRVAPE
EHPVLLTEAPMNPKSNREKMTQIMFETFNVPAFYVSIQAVLSLYSSGRTTGIVLDSGDGV
THVVPIYAGESLPHAILRIDLAGRDLTDYLMKILSERGYSFSTTAEREIVRDIKEKLCYV
ALDFEQEMQTAAQSSSIEKSYELPDGQVITIGNERFRAPEALFHPSVLGLESAGIDQTTY
NSIMKCDVDVRKELYGNIVMSGGTTMFPGIAERMQKEITALAPSSMKVKIIAPPERKYSV
WIGGSILASLTTFQQMWISKQEYDESGPSIVHHKCF
QNDSSKELSNVEDLIQQKVDVLLINPVDSDAVVTAIKEANSKNIPVITIDRSANGGDVVS
HIASDNVKGGEMAAEFIAKALKGKGNVVELEGIPGASAARDRGKGFDEAIAKYPDIKIVA
KQAADFDRSKGLSVMENILQAQPKIDAVFAQNDEMALGAIKAIEAANRQGIIVVGFDGTE
DALKAIKEGKMAATIAQQPALMGSLGVEMADKYLKGEKIPNFIPAELKLITKENVQGGAA
LVNGQKIRVKDKYKLVDPENINLELTVLTLDRNEKERDIRGFISEDLEGVDATLVVHSNN
FTNTILEVGPVTMAGLINLSSTPTNRMIRYDYATKTGQCGGVLCATGKIEGIHVGGNGRQ
GFSAQLKKQYFVEKQ
LGYKIIVEDSQNDSSKELSNVEDLIQQKVDVLLINPVDSDAVVTAIKEAN
SKNIPVITIDRSANGGDVVSHIASDNVKGGEMAAEFIAKALKGKGNVVEL
EGIPGASAARDRGKGFDEAIAKYPDIKIVAKQAADFDRSKGLSVMENILQ
AQPKIDAVFAQNDEMALGAIKAIEAANRQGIIVVGFDGTEDALKAIKEGK
MAATIAQQPALMGSLGVEMADKYLKGEKIPNFIPAELKLITKENVQGGAA
ASEQETLVRPKPLLLKLLKSVGAQKDTYTMKEVLFYLGQYIMTKRLYDEK
QQHIVYCSNDLLGDLFGVPSFSVKEHRKIYTMIYRNLVVVNQQESSDSGT
SVSENRCHLEGGSDQKDLVQELQEEKPSSSHLVSRPSTSSRRRAISETEE
NSDELSGERQRKRHKSDSISLSEDESLALCVIREICCERSSSSESTGTPS
NPDLDAGVSEHSGDWLDQDSVSDQFSVEFEVESLDSEDYSLSEEGQELSD
EDDEVYQVTVYQAGESDTDSFEEDPEISLADYWKCTSCNEMNPPLPSHCN
RCWALRENWLPEDKGKDKGEISEKAKLENSTQAEEGEDVPDCKKTIVNDS
RESCVEENDDKITQASQSQESEDYSQPSTSSSIIYSSQEDVKEFEREETQ
DKEESVESSLPLNAIEPCVICQGRPKNGCIVHGKTGHLMACETCAKKLKK
RNKPCPVCRQPIQMIVLTYFP
While the invention has been described through specific embodiments, routine modifications will be apparent to those skilled in the art and such modifications are intended to be within the scope of the present invention.
This application claims priority to U.S. provisional patent application no. 62/240,863, filed Oct. 13, 2015, the disclosure of which is incorporated herein by reference.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/US2016/056832 | 10/13/2016 | WO | 00 |
| Publishing Document | Publishing Date | Country | Kind |
|---|---|---|---|
| WO2017/066441 | 4/20/2017 | WO | A |
| Number | Name | Date | Kind |
|---|---|---|---|
| 20040118681 | Hellinga et al. | Jun 2004 | A1 |
| 20070020714 | Lee et al. | Jan 2007 | A1 |
| 20080032312 | Amiss et al. | Feb 2008 | A1 |
| 20140259212 | Plesch et al. | Sep 2014 | A1 |
| Entry |
|---|
| Cuneo et al., The backbone structure of the termophilic Termoanaerobacter tengcongensis ribose binding protein is essentially identical to its mesophilic E. coli homolog, BMC Structural Biology, vol. 8, No. 20, pp. 1-11. Mar. 28, 2008. |
| Marvin et al., Engineering Biosensors by Introducing Fluorescent Allosteric Signal Transducers: Construction of a Novel Glucose Sensor, Journal of American Chemical Society, vol. 120, No. 1, pp. 7-11. Jan. 1, 1998. |
| Navdaeva et al., Phosphoenolpyruvate: Sugar Phosphotransferase System from the Hyperthermophilic Thermaonaerobacter tengcongensis, Biochemistry, vol. 50, No. 7, pp. 1184-1193. Feb. 22, 2011. |
| Marshall, K.E., et al., FRET Imaging of Diatoms Expressing a Biosilica-Localized Ribose Sensor, PLoS One, Mar. 21, 2012, vol. 7, No. 3, e33771, pp. 1-8. |
| Francetic, O., et al., Escherichia coli SecB Stimulates Export without Maintaining Export Competence of Ribose-Binding Protein Signal Sequence Mutants, J. Bacteriol., Oct. 1996, vol. 178, pp. 5954-5959. |
| Number | Date | Country | |
|---|---|---|---|
| 20180305700 A1 | Oct 2018 | US |
| Number | Date | Country | |
|---|---|---|---|
| 62240863 | Oct 2015 | US |
